Phase 1
Completed N=7
Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
Source: ClinicalTrials.gov NCT01953783 ↗Enrolled (actual)
7
Serious AEs
14.3%
Results posted
Aug 2020
Primary outcomePrimary: Part A: Cmax: Maximum Observed Plasma Concentration for Ixazomib — 89.06 nanogram per milliliter (ng/mL)
Summary
This is a phase 1, 2-part, open-label study in 4 to 6 pharmacokinetic-evaluable participants with advanced solid tumors or lymphoma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Part A: Cmax: Maximum Observed Plasma Concentration for Ixazomib |
89.06 | — |
| PRIMARY Part A: Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Ixazomib |
0.5000 | — |
| PRIMARY Part A: AUC(0-312): Area Under the Plasma Concentration-time Curve From Time 0 to 312 Hrs Post-dose for Ixazomib |
1181 | — |
| PRIMARY Part A: Cmax: Maximum Observed Plasma Concentration of TRA |
78.80 | — |
| PRIMARY Part A: Tmax: Time to Reach the Cmax for TRA |
0.5000 | — |
| PRIMARY Part A: AUC(0-816): Area Under the Plasma Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA |
2981 | — |
| PRIMARY Part A: Cmax: Maximum Observed Whole Blood Concentration of TRA |
181.6 | — |
| PRIMARY Part A: Tmax: Time to Reach the Maximum Observed Whole Blood Concentration (Cmax) for TRA |
0.6000 | — |
| PRIMARY Part A: AUC(0-816): Area Under the Whole Blood Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA |
29200 | — |
| PRIMARY Part A: Cumulative Percentage of Ixazomib Dose Recovered in the Urine |
3.226 | — |
| PRIMARY Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Feces |
21.80 | — |
| PRIMARY Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Urine |
62.06 | — |
| PRIMARY Part A: Renal Clearance of Ixazomib |
0.1191 | — |
| SECONDARY Ixazomib and Metabolites as Percent of Total Radioactivity in Plasma |
54.2; 7.91; 18.9; 10.6; 3.20 | — |
| SECONDARY Ixazomib and Metabolites as Percent of Total Dose Administered in Urine |
1.30; 0.391; 0.926; 1.61; 1.33; 2.72 | — |
| SECONDARY Ixazomib and Metabolites as Percent of Total Dose Administered in Feces |
13.8; 0.900; 0.111; 0.620; 0.901; 1.14 | — |
| SECONDARY Number of Participants Reporting One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) |
7; 1 | — |
| SECONDARY Number of Participants With TEAEs Related to Investigations System Organ Class for Laboratory Values |
1; 1; 1 | — |
| SECONDARY Number of Participants With TEAEs Related to Vital Signs |
— | — |
Eligibility Criteria
Inclusion Criteria
Each participant must meet all of the following inclusion criteria to be enrolled in the study:
- 18 years or older
- Histologic or cytologic diagnosis of advanced or metastatic solid tumor or lymphoma for which no standard, curative, or life-prolonging therapies exist or are effective
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
- Female participants who are postmenopausal for at least 1 year OR are surgically sterile OR if of childbearing potential, agree to practice 2 effective methods of contraception at the same time during the entire study through 90 days after the last dose of study drug OR agree to practice true abstinence
- Male participants who agree to practice effective barrier contraception during the entire study and through 90 days after the last dose of study drug OR agree to practice true abstinence
- Voluntary written consent
- Suitable venous access for the conduct of blood sampling
- Recovered from the reversible effects of prior anticancer therapy
Exclusion Criteria
Participants meeting any of the following exclusion criteria are not to be enrolled in the study:
- Female participants who are lactating or breastfeeding or have a positive serum pregnancy test
- Serious medical or psychiatric illness that could interfere with the study
- Treatment with any investigational products or radiotherapy within 21 days before the first dose of study drug
- Peripheral neuropathy greater than (>) Grade 2
- Systemic treatment with strong and moderate inhibitors of CYP1A2, strong and moderate inhibitors of CYP3A, or clinically significant CYP3A inducers or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study drug
- Symptomatic brain metastasis. Participants with brain metastases: must have stable neurologic status following local therapy (surgery or radiation) for at least 2 weeks after completion of the definitive therapy; and must be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs)
- Ongoing treatment with corticosteroids
- Major surgery within the 14 days preceding the first dose of study drug
- Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before the first dose of study drug
- Life-threatening illness unrelated to cancer
- Known hepatitis B surface antigen -positive, or known or suspected active hepatitis C infection or human immunodeficiency virus (HIV) positive
- Diagnosed or treated for another malignancy within 2 years before the first dose, OR previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
- Any cardiovascular condition specified in the study protocol
- Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of IXAZOMIB
- History of urinary and/or fecal incontinence
- Inability to comply with study procedures or visit schedule including the requirement for inpatient confinement
Data sourced from ClinicalTrials.gov (NCT01953783). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.